{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:17:06Z","timestamp":1758050226641,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bulcan.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:53:01Z","timestamp":1660747981000},"page":"1125-1131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prise en charge des toxicit\u00e9s de la p\u00e9gaspargase (hors anomalies de la coagulation). Recommandations du comit\u00e9 leuc\u00e9mie de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers de l\u2019enfant et de l\u2019adolescent"],"prefix":"10.1016","volume":"109","author":[{"given":"Marilyne","family":"Poir\u00e9e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne France Ray","family":"Lunven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Plantaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine Thouvenin","family":"Doulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Strullu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bulcan.2022.06.004_bib0175","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.bulcan.2022.06.004_bib0180","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bulcan.2022.06.004_bib0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2021.11.016","article-title":"Hypersensitivity to Pegylated E. coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group","volume":"162","author":"Brigitha","year":"2022","journal-title":"Eur J Cancer."},{"issue":"7","key":"10.1016\/j.bulcan.2022.06.004_bib0190","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","article-title":"Severe pegaspargase hypersensitivity reaction rates (grade\u00a0\u2265\u00a03) with intravenous infusion vs. intramuscular injection: analysis of 54,280\u00a0doses administered to 16,534\u00a0patients on children's oncology group (COG) clinical trials","volume":"59","author":"Burke","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"10.1016\/j.bulcan.2022.06.004_bib0195","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bulcan.2022.06.004_bib0200","first-page":"103","article-title":"High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase","volume":"7","author":"Heitink-Poll\u00e9","year":"2013","journal-title":"JIMD Rep."},{"issue":"3","key":"10.1016\/j.bulcan.2022.06.004_bib0205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","article-title":"Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia","volume":"58","author":"Burke","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"10.1016\/j.bulcan.2022.06.004_bib0210","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/fon-2021-1288","article-title":"Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences","volume":"18","author":"Burke","year":"2022","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.bulcan.2022.06.004_bib0215","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer."},{"issue":"11","key":"10.1016\/j.bulcan.2022.06.004_bib0225","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.004_bib0230","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.bulcan.2022.06.004_bib0235","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.leu.2400703","article-title":"Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity","volume":"11","author":"Hoogerbrugge","year":"1997","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2022.06.004_bib0240","first-page":"351","article-title":"Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma","volume":"27","author":"Tozuka","year":"1997","journal-title":"Ann Clin Lab Sci."},{"issue":"5","key":"10.1016\/j.bulcan.2022.06.004_bib0245","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3324\/haematol.2016.160507","article-title":"Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia","volume":"102","author":"Mogensen","year":"2017","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.bulcan.2022.06.004_bib0250","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/bloodadvances.2021005631","article-title":"Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008\u00a0study","volume":"6","author":"Lynggaard","year":"2022","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.bulcan.2022.06.004_bib0255","first-page":"987","article-title":"How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.bulcan.2022.06.004_bib0260","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pbc.20986","article-title":"Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis","volume":"50","author":"Ridola","year":"2008","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.004_bib0265","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12185-011-0966-9","article-title":"Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?","volume":"94","author":"Lashkari","year":"2011","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.06.004_bib0270","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2022.06.004_bib0275","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.bulcan.2022.06.004_bib0280","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2016.7","article-title":"Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia","volume":"17","author":"Alachkar","year":"2017","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"10.1016\/j.bulcan.2022.06.004_bib0285","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1016\/j.apsb.2021.11.022","article-title":"Mechanistic studies of PEG-asparaginase-induced liver injury and hepatic steatosis in mice","volume":"11","author":"Kumar","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"10.1016\/j.bulcan.2022.06.004_bib0290","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2022.06.004_bib0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2017.12.013","article-title":"Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses","volume":"66","author":"Burke","year":"2018","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.bulcan.2022.06.004_bib0300","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1078155217710714","article-title":"Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature","volume":"24","author":"Blackman","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"21","key":"10.1016\/j.bulcan.2022.06.004_bib0305","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.06.004_bib0310","doi-asserted-by":"crossref","first-page":"e000858","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open\u00a0\u2013\u00a0cancer horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2022.06.004_bib0315","first-page":"18","article-title":"Diabetic ketoacidosis following PEG-asparaginase therapy","volume":"2018","author":"Ahmad","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2022.06.004_bib0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008\u00a0treatment of patients 1\u201345\u00a0years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.004_bib0325","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14\u00a0severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bulcan.2022.06.004_bib0330","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jpedsurg.2011.03.044","article-title":"Acute pancreatitis in children: spectrum of disease and predictors of severity","volume":"46","author":"Lautz","year":"2011","journal-title":"J Pediatr Surg."},{"issue":"9","key":"10.1016\/j.bulcan.2022.06.004_bib0335","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bulcan.2022.06.004_bib0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/jayao.2015.0014","article-title":"Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase","volume":"4","author":"Boissel","year":"2015","journal-title":"J Adolesc Young Adult Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122002703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122002703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:21Z","timestamp":1757792181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122002703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0007455122002703"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.06.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des toxicit\u00e9s de la p\u00e9gaspargase (hors anomalies de la coagulation). Recommandations du comit\u00e9 leuc\u00e9mie de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers de l\u2019enfant et de l\u2019adolescent","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}